An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0

被引：56

作者：

Sullivan, Ryan J. ^{[1
]}

Atkins, Michael B. ^{[2
]}

Kirkwood, John M. ^{[3
]}

Agarwala, Sanjiv S. ^{[4
,5
]}

Clark, Joseph, I ^{[6
]}

Ernstoff, Marc S. ^{[7
]}

Fecher, Leslie ^{[8
]}

Gajewski, Thomas F. ^{[9
]}

Gastman, Brian ^{[10
]}

Lawson, David H. ^{[11
]}

Lutz, Jose ^{[12
]}

McDermott, David F. ^{[13
]}

Margolin, Kim A. ^{[14
]}

Mehnert, Janice M. ^{[15
]}

Pavlick, Anna C. ^{[16
]}

Richards, Jon M. ^{[17
]}

Rubin, Krista M. ^{[1
]}

Sharfman, William ^{[18
]}

Silverstein, Steven ^{[19
]}

Slingluff, Craig L., Jr. ^{[20
]}

Sondak, Vernon K. ^{[21
]}

Tarhini, Ahmad A. ^{[22
]}

Thompson, John A. ^{[23
]}

Urba, Walter J. ^{[24
]}

White, Richard L. ^{[25
]}

Whitman, Eric D. ^{[26
]}

Hodi, F. Stephen ^{[27
]}

Kaufman, Howard L. ^{[1
]}

机构：

[1] Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA

[2] Georgetown Univ, Washington, DC 20057 USA

[3] Univ Pittsburgh, Pittsburgh, PA 15213 USA

[4] St Lukes Canc Ctr, Center Valley, PA 18034 USA

[5] Temple Univ, Center Valley, PA 18034 USA

[6] Loyola Univ Med Ctr, Maywood, IL 60153 USA

[7] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

[8] Univ Michigan, Ann Arbor, MI 48109 USA

[9] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[10] Cleveland Clin, Cleveland, OH 44195 USA

[11] Emoiy Winship Canc Inst, Atlanta, GA 30322 USA

[12] Mt Sinai Med Ctr, Miami Beach, FL 33140 USA

[13] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[14] City Hope Natl Med Ctr, Duarte, CA 91010 USA

[15] Rutgers Canc Inst New Jersey, New Brunswick, NJ 08901 USA

[16] NYU, Canc Inst, New York, NY 10016 USA

[17] Lutheran Gen Hosp, Park Ridge, IL 60068 USA

[18] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21231 USA

[19] Melanoma Res Fdn, Woodcliff Lake, NJ 07077 USA

[20] Univ Virginia, Charlottesville, VA 22908 USA

[21] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

[22] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44195 USA

[23] Seattle Canc Care Alliance, Seattle, WA 98109 USA

[24] Providence Canc Ctr, Earle A Chiles Res Inst, Portland, OR 97213 USA

[25] Carolinas Med Ctr, Charlotte, NC 28204 USA

[26] Carol G Simon Canc Ctr, Morristown, NJ 07046 USA

[27] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2018年 / 6卷

关键词：

Guidelines; Immunotherapy; Melanoma; Treatment; COOPERATIVE-ONCOLOGY-GROUP; STAGE-III MELANOMA; RECOMBINANT INTERLEUKIN-2 THERAPY; HIGH-DOSE INTERFERON-ALPHA-2B; IPILIMUMAB PLUS DACARBAZINE; GROUP-AMERICAN COLLEGE; HIGH-RISK MELANOMA; QUALITY-OF-LIFE; METASTATIC MELANOMA; ADJUVANT THERAPY;

D O I：

10.1186/s40425-018-0362-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Cancer immunotherapy has been firmly established as a standard of care for patients with advanced and metastatic melanoma. Therapeutic outcomes in clinical trials have resulted in the approval of 11 new drugs and/or combination regimens for patients with melanoma. However, prospective data to support evidence-based clinical decisions with respect to the optimal schedule and sequencing of immunotherapy and targeted agents, how best to manage emerging toxicities and when to stop treatment are not yet available. Methods: To address this knowledge gap, the Society for Immunotherapy of Cancer (SITC) Melanoma Task Force developed a process for consensus recommendations for physicians treating patients with melanoma integrating evidence-based data, where available, with best expert consensus opinion. The initial consensus statement was published in 2013, and version 2.0 of this report is an update based on a recent meeting of the Task Force and extensive subsequent discussions on new agents, contemporary peer-reviewed literature and emerging clinical data. The Academy of Medicine (formerly Institute of Medicine) clinical practice guidelines were used as a basis for consensus development with an updated literature search for important studies published between 1992 and 2017 and supplemented, as appropriate, by recommendations from Task Force participants. Results: The Task Force considered patients with stage II-IV melanoma and here provide consensus recommendations for how they would incorporate the many immunotherapy options into clinical pathways for patients with cutaneous melanoma. Conclusion: These clinical guidleines provide physicians and healthcare providers with consensus recommendations for managing melanoma patients electing treatment with tumor immunotherapy.

引用

页数：23

共 96 条

[1] Outcomes of Patients With Metastatic Melanoma Treated With Immunotherapy Prior to or After BRAF Inhibitors [J].

Ackerman, Allison ;

Klein, Oliver ;

McDermott, David F. ;

Wang, Wei ;

Ibrahim, Nageatte ;

Lawrence, Donald P. ;

Gunturi, Anasuya ;

Flaherty, Keith T. ;

Hodi, F. Stephen ;

Kefford, Richard ;

Menzies, Alexander M. ;

Atkins, Michael B. ;

Long, Georgina V. ;

Sullivan, Ryan J. .

CANCER, 2014, 120 (11) :1695-1701

[2] Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697) [J].

Agarwala, Sanjiv S. ;

Lee, Sandra J. ;

Yip, Waiki ;

Rao, Uma N. ;

Tarhini, Ahmad A. ;

Cohen, Gary I. ;

Reintgen, Douglas S. ;

Evans, Terry L. ;

Brell, Joanna M. ;

Albertini, Mark R. ;

Atkins, Michael B. ;

Dakhil, Shaker R. ;

Conry, Robert M. ;

Sosman, Jeffrey A. ;

Flaherty, Lawrence E. ;

Sondak, Vernon K. ;

Carson, William E. ;

Smylie, Michael G. ;

Pappo, Alberto S. ;

Kefford, Richard F. ;

Kirkwood, John M. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (08) :885-U123

[3] Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma [J].

Andtbacka, Robert H. I. ;

Kaufman, Howard L. ;

Collichio, Frances ;

Amatruda, Thomas ;

Senzer, Neil ;

Chesney, Jason ;

Delman, Keith A. ;

Spitler, Lynn E. ;

Puzanov, Igor ;

Agarwala, Sanjiv S. ;

Milhem, Mohammed ;

Cranmer, Lee ;

Curti, Brendan ;

Lewis, Karl ;

Ross, Merrick ;

Guthrie, Troy ;

Linette, Gerald P. ;

Daniels, Gregory A. ;

Harrington, Kevin ;

Middleton, Mark R. ;

Miller, Wilson H., Jr. ;

Zager, Jonathan S. ;

Ye, Yining ;

Yao, Bin ;

Li, Ai ;

Doleman, Susan ;

VanderWalde, Ari ;

Gansert, Jennifer ;

Coffin, Robert S. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) :2780-U98

[4]

[Anonymous], 2020, JAMA, DOI [DOI 10.1001/JAMA.2020.2717, DOI 10.1001/JAMA.2014.13943]

[5] Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program [J].

Ascierto, Paolo Antonio ;

Simeone, Ester ;

Sileni, Vanna Chiarion ;

Del Vecchio, Michele ;

Marchetti, Paolo ;

Cappellini, Gian Carlo Antonini ;

Ridolfi, Ruggero ;

de Rosa, Francesco ;

Cognetti, Francesco ;

Ferraresi, Virginia ;

Testori, Alessandro ;

Queirolo, Paola ;

Bernengo, Maria Grazia ;

Guida, Michele ;

Galli, Luca ;

Mandala, Mario ;

Cimminiello, Carolina ;

Rinaldi, Gaetana ;

Carnevale-Schianca, Fabrizio ;

Maio, Michele .

CANCER INVESTIGATION, 2014, 32 (04) :144-149

[6] High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].

Atkins, MB ;

Lotze, MT ;

Dutcher, JP ;

Fisher, RI ;

Weiss, G ;

Margolin, K ;

Abrams, J ;

Sznol, M ;

Parkinson, D ;

Hawkins, M ;

Paradise, C ;

Kunkel, L ;

Rosenberg, SA .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116

[7]

Atkins MB, 2000, CANCER J SCI AM, V6, pS11

[8] IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade [J].

Ayers, Mark ;

Lunceford, Jared ;

Nebozhyn, Michael ;

Murphy, Erin ;

Loboda, Andrey ;

Kaufman, David R. ;

Albright, Andrew ;

Cheng, Jonathan D. ;

Kang, S. Peter ;

Shankaran, Veena ;

Piha-Paul, Sarina A. ;

Yearley, Jennifer ;

Seiwert, Tanguy Y. ;

Ribas, Antoni ;

McClanahan, Terrill K. .

JOURNAL OF CLINICAL INVESTIGATION, 2017, 127 (08) :2930-2940

[9] Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis [J].

Beaver, Julia A. ;

Hazarika, Maitreyee ;

Mulkey, Flora ;

Mushti, Sirisha ;

Chen, Huanyu ;

He, Kun ;

Sridhara, Rajeshwari ;

Goldberg, Kirsten B. ;

Chuk, Meredith K. ;

Chi, Dow-Chung ;

Chang, Jennie ;

Barone, Amy ;

Balasubramaniam, Sanjeeve ;

Blumenthal, Gideon M. ;

Keegan, Patricia ;

Pazdur, Richard ;

Theoret, Marc R. .

LANCET ONCOLOGY, 2018, 19 (02) :229-239

[10] Targeted Therapies for Melanoma Brain Metastases [J].

Berghoff, Anna S. ;

Preusser, Matthias .

CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2017, 19 (04)

← 1 2 3 4 5 6 7 8 9 10 →